Skip to main content
. 2023 Feb 24;15(3):765. doi: 10.3390/pharmaceutics15030765

Figure 2.

Figure 2

Ubiquitination mechanisms of reported PROTAC-based technologies for targeting TFs or RBPs. These PROTAC molecules essentially consist of an E3 binder, a linking moiety, and a POI binder. The degradation of the POI is UPS-dependent.